Clinical trials
Completed Choroidal Neovascularization trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
135 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 2 |
| 2001 | 3 |
| 2002 | 2 |
| 2003 | 3 |
| 2004 | 5 |
| 2005 | 9 |
| 2006 | 11 |
| 2007 | 16 |
| 2008 | 12 |
| 2009 | 4 |
| 2010 | 14 |
| 2011 | 6 |
| 2012 | 8 |
| 2013 | 7 |
| 2014 | 3 |
| 2015 | 6 |
| 2016 | 2 |
| 2017 | 3 |
| 2018 | 2 |
| 2019 | 3 |
| 2020 | 3 |
| 2021 | 6 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 135 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novartis Pharmaceuticals | 19 |
| National Eye Institute (NEI) | 10 |
| Notal Vision Ltd. | 6 |
| Novartis | 6 |
| GlaxoSmithKline | 5 |
| Johns Hopkins University | 5 |
| Alcon Research | 4 |
| Bayer | 4 |
| Medical University of Vienna | 4 |
| Allergan | 3 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Choroidal Neovascularization | 135 |
| Macular Degeneration | 86 |
| Geographic Atrophy | 10 |
| Vision Disorders | 9 |
| Wet Macular Degeneration | 8 |
| Macular Edema | 7 |
| Myopia, Degenerative | 6 |
| Retinal Vein Occlusion | 6 |
| Angioid Streaks | 5 |
| Diabetic Retinopathy | 5 |
Trials
Showing 26 to 50 of 135. Each trial links to its page on Pharma Observatory.
35 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.